GlassScriptPhysician profile
Guillermo Marrero
NPI 1245211044
$2,761.06
in general payments reported to CMS, 2019-2025
29 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $163 · 2021: $592 · 2022: $512 · 2023: $671 · 2024: $385 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $591.73 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Vanda Pharmaceuticals INC. | $315.36 | 2022-2023 | Hetlioz, Fanapt |
| Abbvie INC. | $231.37 | 2020-2025 | |
| Lilly USA, LLC | $224.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $191.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $170.83 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.09 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $101.52 | 2021-2022 | |
| Pfizer INC. | $81.66 | 2019-2025 | |
| Amarin Pharma, INC. | $79.37 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $74.23 | 2020-2021 | |
| Abbott Laboratories | $67.50 | 2021-2024 | Freestyle Libre 3 |
| Allergan, INC. | $63.67 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.82 | 2021-2025 | Xifaxan |
| Amgen INC. | $54.40 | 2022-2025 | Otezla, Repatha, Evenity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $46.06 | 2021-2022 | |
| Astellas Pharma US INC | $42.45 | 2019-2023 | Veozah |
| Amneal Pharmaceuticals LLC | $33.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.38 | 2022-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $23.20 | 2022 | |
| Organogenesis INC. | $18.18 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.09 | 2022 | |
| Currax Pharmaceuticals LLC | $17.55 | 2025 | Contrave |
| Eisai INC. | $16.31 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.54 | 2025 | Nuzyra |
| Seqirus USA INC | $15.43 | 2025 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $14.93 | 2022 | |
| Exact Sciences Corporation | $14.60 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Marrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.